Ophthalmic H1 antihistamine + mast cell stabiliser
Epinastine hydrochloride
Brand names: Relestat
Adult dose
Dose: 1 drop into each eye BD
Route: Ophthalmic
Frequency: BD
Clinical pearls
- Allergic conjunctivitis — RCOphth and BSACI guidance
- Dual-action benefit for both acute symptoms and prevention
Contraindications
- Hypersensitivity
Side effects
- Eye irritation
- Burning
- Headache
- Dry eye
Interactions
- Contact lenses (remove before instillation; replace 15 min later)
Monitoring
- Symptom response
- IOP not affected
Reference: BNF; RCOphth; BSACI; SmPC; https://bnf.nice.org.uk/drugs/epinastine-hydrochloride/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Urticaria Activity Score (UAS7) · Urticaria
- C-Peptide to Glucose Ratio · Diabetes Classification
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- HCT-CI — Haematopoietic Cell Transplant Comorbidity Index · Risk Stratification
Pathways
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme